Figure 2.

The crosstalk between phosphorylation and ubiquitination influences tumorigenesis and related therapies (A) Crosstalk suppresses tumorigenesis by promoting the degradation of some oncoproteins or inhibiting the degradation of tumor suppressors, and promotes tumorigenesis by inhibiting the degradation of various oncoproteins. (B) Activators and inhibitors of kinases which can regulate the crosstalk between phosphorylation and ubiquitination can be used for tumor therapy. Kinase activators can be used to promote the phosphorylation and the ubiquitinated degradation of those oncoproteins when phosphorylation facilitates their interaction with CRLs, and promote the phosphorylation but inhibit the ubiquitinated degradation of those tumor suppressors when phosphorylation restrains their interaction with CRLs. Kinase inhibitors can be used to suppress the phosphorylation but promote the ubiquitinated degradation of those oncoproteins when phosphorylation restrains their interaction with CRLs.